Ipsen’s Dysport next generation shows safety and efficacy in Phase III

5 February 2014

French drugmaker Ipsen (Euronext: IPN) today announced the results of the international Phase III clinical trial of Dysport (abobotulinumtoxinA) next generation (DNG) in cervical dystonia and the results of the European Phase II clinical trial of DNG in glabellar lines.

DNG was clinically and statistically superior to placebo in the cervical dystonia Phase III study at the dose of 500 units at week four after single dose. After repeated dose, DNG showed comparable efficacy to that of Dysport as observed in former Phase III studies. DNG was clinically and statistically superior to placebo and comparable to Dysport in the glabellar lines Phase II study at the dose of 50 units after single dose.

Safe and efficacious

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK